Partnering for Innovation in Manufacturing & Supply

How are bio/pharma companies and their partners collaborating to resolve the difficult challenges that arise in development, manufacturing, and the supply chain? DCAT Member Companies are invited to apply to share fresh insights, best practices, and lessons learned at a DCAT Week program. Applications close January 13, 2025.

How are bio/pharma companies and their partners collaborating to resolve the difficult challenges that arise in development, manufacturing, and the supply chain? DCAT Member Companies are invited to apply to share fresh insights, best practices, and lessons learned at a DCAT Week program. Applications deadline extended and closes January 24, 2025.

By Patricia Van Arnum, Editorial Director, DCAT, [email protected]

A solutions-based program at DCAT Week
Innovation is essential for achieving operational excellence and delivering value. A DCAT Week 2025 program, Partnering for Innovation in Manufacturing & Supply, will feature case studies on how bio/pharma companies and their partners have collaborated to resolve the hard challenges that arise in development, manufacturing, and the supply chain. Partner companies include CDMOs/CMOs, suppliers of raw materials or other inputs, technology services providers, or other companies, including other bio/pharma companies.

The 90-minute program will consist of three co-presentations (20 minutes each) between a bio/pharma company and partner company. It is a way to share fresh insights, best practices, and lessons learned to a well-informed business audience of senior to mid-level executives.

DCAT Member Companies are invited to submit applications by January 24, 2025, for consideration of their case study.  A task force of industry colleagues selected from DCAT volunteer committees and leadership will evaluate all applications and select three case studies providing the most useful, valuable, and innovative insight of utility and interest to DCAT Member Companies. Presentations will be due March 3, 2025. Further information, including the online application to apply, may be found here.

Topics of interest
The case studies may address a range of topics—but must reflect an innovative or better approach taken in manufacturing or supply. Potential topics can include:

  • New technologies in drug-substance and drug-product manufacturing or packaging;
  • Cost optimization and improved production economics;
  • Collaborative project management;
  • Increasing supply-chain performance, resiliency, or visibility;
  • Upgraded inventory management;
  • Collaborative demand and supply planning/forecasting;
  • Sustainability improvements: technology, manufacturing & metrics;
  • Digitalization to better performance, including regulatory compliance; or
  • Other innovation in manufacturing and supply.

The program provides a way to stand out among your peers in the industry by showing  resourceful and effective ways to advance manufacturing and supply. Further information, including the online application to apply, may be found here.

Recent Feature Articles

Biomanufacturing Growth: Capacity Trends & CDMO Insights & Outlook

By
What is the outlook for biomanufacturing (drug substance)? How is industry capacity trending, and what is the outlook for outsourcing? A recent study by BioPlan Associates reveals key insights.

PhRMA Raises A Legal Challenge To Most-Favored-Nation Drug Pricing

By
The Pharmaceutical Research and Manufacturers of America (PhRMA) has filed a legal complaint that challenges the US government’s most-favored-nation drug pricing policy in the GLOBE Model under Medicare Part B.

What Is New and Upcoming in Small-Molecule Drugs?

By
Which small-molecule drugs are making the mark in 2026 in new drug approvals or in recently or soon-to-be launched drugs? DCAT Value Chain Insights takes an inside look.

US Gov’t Makes Next Move to Onshore Mfg of Generics

By
The White House is moving to identify new and unused domestic, US-based, and near-shore production capacity to meet a goal of localizing manufacturing of essential medicines.